5 reports

  • 8.1 REFERENCES

Cancer Discovery; ##(##): ##-## Hanahan D and Weinberg RA (2011).

  • Cancer
  • Cancer Immunotherapy
  • Lung Cancer
  • Therapy
  • Cellectis S.A.
  • MARKET LANDSCAPE
  • 12.5.3. PRODUCT PORTFOLIO

IN CASE OF BREAST CANCER, SOME ANTIGENS EXPRESSED ON THE TUMOUR CELLS ARE NY-ESO-##, MAGE-## AND HER-##.

  • Cancer
  • Cell Therapy
  • Motor Vehicle
  • Therapy
  • Cellectis S.A.
  • 5.3 CELLECTIS

Bayer anticipates peak sales potential of more than EUR ## billion (about US$ ##. ## bln) for the cancer drug Xofigo (Press Release Sep ##, 2016).

  • Cancer
  • Monoclonal Antibody
  • Therapy
  • AstraZeneca PLC
  • Cellectis S.A.

This version of the DART molecule enables the cancer-fighting properties of the immune effector cells, such as T lymphocytes, to: (##) recognize and bind to structures expressed on a cancer cell, (##) recruit all types of cytotoxic, or cell killing, T cells, irrespective of

  • Cancer
  • Cell Therapy
  • Cellectis S.A.
  • Janssen Biotech, Inc.
  • Kyowa Hakko Kirin Co., Ltd.
  • Cellectis S.A. - Dormant Developmental Projects,2016
  • UCART-22 - Drug Profile

The stimulated immune responses may destroy the cancer cells.

  • Cancer
  • World
  • Company Operations
  • Product Initiative
  • Cellectis S.A.